

EMLc

ATC codes: J01DD04

| | |
|--------------------------|--|
| Indication | Bacterial meningitis ICD11 code: 8E71.OZ |
| INN | Ceftriaxone |
| Medicine type | Chemical agent |
| Antibiotic groups |  WATCH |
| List type | Core (EML) (EMLc) |
| Additional notes | Do not administer with calcium and avoid in infants with hyperbilirubinaemia. |
| Formulations | Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt) ; 1 g in vial powder for injection (as sodium salt) ; 2 g in vial powder for injection (as sodium salt) (EML) ; 500 mg in vial powder for injection (as sodium salt) |
| EML status history | First added in 2017 (TRS 1006) Changed in 2021 (TRS 1035) Changed in 2023 (TRS 1049) |
| Sex | All |
| Age | Also recommended for children |
| Age restriction | > 41 weeks corrected gestational age |
| Therapeutic alternatives | The recommendation is for this specific medicine |
| Patent information | Patents have expired in most jurisdictions Read more about patents .  |
| Wikipedia | Ceftriaxone  |
| DrugBank | Ceftriaxone  |

Expert Committee recommendation

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of new strength formulations of cefotaxime (powder for injection: 500 mg; 1 g; 2 g (as sodium) in vial) to the EML and EMLc. - the addition of a new strength formulation of ceftriaxone (powder for injection: 500 mg (as sodium) in vial) to the EML and EMLc. - the addition of new formulations of amoxicillin (dispersible, scored tablet, 250 mg and 500 mg) to the EMLc. - the deletion of oral formulations of chloramphenicol (capsule 250 mg and oral liquid 150 mg/5 mL (as palmitate)) from the EML and EMLc.

EML recommendations: Bacterial meningitis

First choice**Second choice**

cefotaxime

ampicillin

ceftriaxone

benzylpenicillin

amoxicillin

chloramphenicol

